Progress of Cancer Precision Medical by Approval of Medical Insurance of Cancer Gene Panel Test

Public medical insurance is applied to the genetic testing system of Cancer genomic medicine , which chooses the most appropriate drug from the result of examining the gene mutation of the patients cancer cell. The curtain of cancer genomic medicine era was opened. Healthcare professionals want to understand the possibilities and limitations of testing and to steadily develop this medical technology. The testing equipment are the OncoGuide™ NCC oncopanel system developed by the National Cancer Research Center and the Foundation One CDx produced by Chugai Pharmaceutical Company. In each case, more than 100 types of cancer related gene mutations can be examined at one time. The number of patients eligible for genome medical treatment is estimated to be approximately 26,000 for patients with solid and rare cancers without standard treatment. Until now, it cost several hundred thousand yen for the patient. Patients who are said to have no cure are tested to a small degree, are looking for anti cancer drugs that could be used. With public health insurance, a series of tests cost 560,000 yen, for people under the age of 70 with average income, medical expenses are about 80,000 yen. It will be able to receive examinations widely at less than 200 medical institutions nationwide. This new cancer treatment gives new hope to patients with cancer. However, patients with cancer should not have excessive expectations. It is necessary to keep in mind that there is a limit to clinical cancer treatment. Takuma Hayashi | Takashi Ura | Ikuo Konishi ""Progress of Cancer Precision Medical by Approval of Medical Insurance of Cancer Gene Panel Test"" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-4 | Issue-2 , February 2020, URL: https://www.ijtsrd.com/papers/ijtsrd29914.pdf Paper Url : https://www.ijtsrd.com/medicine/other/29914/progress-of-cancer-precision-medical-by-approval-of-medical-insurance-of-cancer-gene-panel-test/takuma-hayashi